An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States

Completed · Phase 2

Conditions studied: Parkinson's Disease

In brief

The purpose of this study is to evaluate the safety and efficacy of the long-term treatment of entacapone in patients with Parkinson's disease with end-of-dose wearing-off. This study is not recruiting patients in the United States.

Key facts

Study ID

NCT00237263

Run by

Novartis

People needed

285

Starts

2003-02-01

Expected to finish

2007-07-01

Last updated by the study team

2024-01-11

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Attended the Phase IIb study
• Able to fill out the patient diary

You may not qualify if…

• Serious heart, pulmonary, renal, hepatic or gastrointestinal disease
• Dementia symptoms
• Pregnant or nursing (lactating) women
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Novartis Pharmaceuticals — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.